Role of posaconazole in the treatment of oropharyngeal candidiasis
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz11Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USAAbstract: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a bro...
Main Authors: | Voichita Ianas, Kathryn R Matthias, Stephen A Klotz |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-06-01
|
Series: | Infection and Drug Resistance |
Online Access: | http://www.dovepress.com/role-of-posaconazole-in-the-treatment-of-oropharyngeal-candidiasis-a4689 |
Similar Items
-
Successful Treatment of Chronic Mucocutaneous Candidiasis Caused by Azole-Resistant Candida albicans with Posaconazole
by: Davide Firinu, et al.
Published: (2011-01-01) -
Predicting and evaluating outcome in oropharyngeal candidiasis (OPC) in AIDS
by: Hood, Stephen Victor
Published: (2000) -
Oropharyngeal Candidiasis as a Presenting Symptom of Crohn’s Disease
by: Muhammad Sharif, et al.
Published: (2020-04-01) -
Oropharyngeal Candidiasis: Fungal Invasion and Epithelial Cell Responses.
by: Marc Swidergall, et al.
Published: (2017-01-01) -
Oropharyngeal candidiasis in children with lymphohematopoietic malignancies in Mashhad, Iran
by: Fariba Berenji, et al.
Published: (2015-03-01)